Background: Synthetic cannabinoids (SCs), originally developed to reproduce the effects of Δ-9 tetrahydrocannabinol (THC), have been marketed as BSpice^and BK2^and gained popularity among adolescents and adults. The enhanced toxicity of SCs is postulated to be secondary to excessive agonism at cannabinoid receptors 1 and 2 and possibly other receptors. In April 2015, there was a large increase in nationwide reports of SC exposures to poison control centers (PCCs). Research Question: What are the clinical manifestations associated with exposures to MAB-CHMINACA (N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 Hindazole-3-carboxamide), a novel carboxamide indazole SC? Methods: A retrospective case-series describing clinical toxicity of 11 patients who presented to a single tertiary care facility between April 20 and June 6 of 2016 with serologic confirmation of MAB-CHMINACA. Liquid chromatography/mass spectroscopy (LC/MS) was used to identify other substances or adulterants.
The following case-specific information was reported: clinical signs/symptoms, vital signs, need for endotracheal intubation, qualitative serum levels of MAB-CHMINACA, other identified substances, and outcome. Results: Seven (63.6%) of the 11 patients were men; ages ranged from 13 to 50 years old (YO). Ten patients were unresponsive, nine required intubation, and three had seizure activity. Severe agitation/combativeness 9/11 (82%), tachycardia 7/11(64%), and hallucinations 3/11(27%) were reported. One patient was discharged within 24 h; the remainder were hospitalized for between 2 and 8 days. There was one death in a 20 YO man found unresponsive and hyperthermic with decorticate posturing; care was withdrawn on hospital day 7 secondary to anoxic brain injury. All patients had other substances found on LC/MS, including acetaminophen, caffeine, opiates, and SSRIs. There was no correlation between severity of symptoms and qualitative level of MAB-CHMINACA. Conclusion: SCs, specifically MAB-CHMINACA, are associated with significant toxicity. Clinical effects include agitation, tachycardia, unresponsiveness, hyperthermia, and death. Aggressive care may be required. Critique: This case series was limited by a small patient population from one geographical location. Other substances of abuse were found on LC/MS, which may have affected outcomes, and only qualitative (not quantitative) MAB-CHMINACA levels were reported. Implication for Toxicologists: MAB-CHMINACA may present differently than previous reports of SC intoxication. Toxicologists and PCCs should notify treating physicians about the risks for severe clinical effects. Background: Nitrous oxide (N 2 O) is used as a medical anesthetic with analgesic properties and commercially in the food industry as a mixing and foaming agent. Due to its euphoric effects, via N-methyl-D-aspartate antagonism, it is also used recreationally. Few studies have evaluated the prevalence and patterns of N 2 O abuse. Research Question: What are the user characteristics, patterns of consumption, and experienced adverse effects (AEs) of N 2 O abuse? Methods: An anonymous, internet based survey was produced and distributed by the Global Drug Survey (GDS) and is currently the largest survey of recreational drug use in the world. Participants were recruited on social media and through collaboration with media organizations. The data were obtained from a 2013 survey and included 74,864 subjects from 150 countries. The survey asked about use of 134 legal and illegal substances; demographic information was also obtained. Responders who endorsed N 2 O use were then asked about use during their lifetime, last year, and last month. They were also queried on place of purchase, method of use, and where and how much they used. Quantity was evaluated by asking how many Bhits^used; estimated to equal the amount contained in a whippet cylinder or enough to fill one balloon. Any experienced AEs and responder's concern regarding the mental and physical health effects of N 2 O use were also recorded. Results: The prevalence of N 2 O use varied widely between countries. Six countries (United Kingdom (UK), USA, New Zealand, Australia, Switzerland, and Germany) were selected for specific analysis. The UK had the highest rates of use, with lifetime use of 38.6% and a 7.7% 30-day use. The USA had a lifetime use of 29.4% and last 30-day use of 2.9%. Germany was the lowest of these countries, with an 11.2% lifetime and 0.9% 30-day use. The median user age was 22 years old (IQR 20-27); more men (7.2%) responded yes to N 2 O use than women (4.9%). The majority (80.6%) consumed N 2 O by inhaling balloons, mostly by mouth (98.3%); whipped-cream dispensers were used by 15.9%. An overwhelming majority (89.2%) used it with other drugs. The median number of hits per episode of use was 5 (IQR 3-10). Places of purchase varied and included friends (38.8%), supermarkets (34.4%), the Internet (29.3%), and festivals (28.7%); dealers, adult stores, and head shops were all <10%. Places of use included private house parties (72.2%), festivals (53.3%), homes (51.4%), and clubs (31.8%0). Hallucinations (36.3%) and confusion (31.5%) were the most commonly reported AEs. Fainting (10.4%), nausea (9.7%), and persistent numbness (5.9%) were less frequent. Incidence of AEs appeared to increase with consumption of larger quantities per session. The majority of users were not worried about the mental (77.5%) or physical (76.5%) effects of N 2 O use. Nitrous oxide was the 8th most commonly reported abused substance in the UK but outside of the top 10 abused substances worldwide. Conclusion: Recreational use of N 2 O is popular though infrequent. The incidence of AEs appears to correlate directly with amounts consumed. Critique: The survey was anonymous, preventing validation of responses. Importantly, this was a global survey with almost 75,000 responses. However, there was inherent selection bias in purposive sampling and may not be representative of the general population. The majority of users consumed N 2 O concomitantly with other substances, confounding the validity of causation for AEs. The results also may not be globally applicable, as a substantial percentage of respondents were from the UK, where prevalence was higher than other countries. Implication for Toxicologists: N 2 O use is prevalent, and awareness of use patterns and AEs should assist with the management of these patients. Presented data offer educational opportunities for PCCs. Background: Many states are considering legalized marijuana for medical or recreational purposes. Physicians and policymakers need to understand potential impacts on mental health and substance use in those who use cannabis. Research Question: What are the risks of mental health and substance use disorders in patients who use cannabis? Methods: This was a prospective epidemiologic survey of US adults who were interviewed over 3 years. At the first interview, subjects were divided into cannabis users and non-cannabis users. Three years later, the same people were re-interviewed and screened for mental health disorders and substance use disorders. Multiple regression analysis and propensity score matching were used to estimate the strength of association between cannabis use (as measured during the first interview) and the incidence and prevalence of mental health and substance use disorders (measured in the second interview). Results: A total of 34,653 respondents were included in analysis; 14,564 [47.9%] were male; the mean age was 45.1 years [SD 17.3] . Among these subjects, cannabis use was reported by 1279 (3.69%) during the initial interview and was associated with (any) substance use disorders identified upon reinterview: odds ratio [OR] 6.2 (95%CI, 4.1-9.4); (any) alcohol use disorder: OR, 2.7 (95%CI, 1.9-3.8); (any) cannabis use disorder: OR 9.5 (95%CI, 6.4-14.1); (any) other drug use disorder: OR 2.6 (95%CI, 1.6-4.4); and nicotine dependence: OR 1.7 (95%CI, 1.2-2.4). Cannabis use was not associated with any mood disorder [OR 1.1 (95%CI, 0.8-1.4)] or anxiety disorder [OR 0.9 (95%CI, 0.7-1.1)]. Conclusion: Cannabis use was associated with an increased incidence and prevalence of substance use disorders including nicotine dependence, alcohol use disorder, cannabis use disorder, and other drug use disorder. However, there was not a statistically significant association of cannabis use with mood or anxiety disorders. Critique: While this was a prospective study, it cannot establish a causal relationship between cannabis use and future substance abuse. It should be no surprise that people who try psychoactive substances are more likely to use other psychoactive substances in the future. Statistical analysis controlling for confounding variables found no statistically significant relationship between cannabis use and mood disorders. Some psychiatric disorders, however, were not assessed. Implication for Toxicologists: Toxicologists should be aware of the association between cannabis use and future use of other substances. Likewise, knowledge about a lack of an association between cannabis use and the future development of some psychiatric disorders should be acknowledged. Further studies are needed to confirm these findings and establish causation. Background: It has been well documented that no current pharmacotherapy is available to engage and retain individuals in the treatment and reduction of cocaine use disorder. Prior research has targeted primary opioid misusers who were also cocaine users. A previous study showed a therapeutic effect of buprenorphine on cocaine use that appeared to be independent of effects on opioid use. In a rodent model, the combination of buprenorphine and naltrexone reduced cocaine self-administration. Research Question: Can buprenorphine and naloxone, initiated after extended release (ER) injection of naltrexone, safely and effectively reduce cocaine use in patients with cocaine dependence and past/current opioid use or dependence? Methods: This was a multi-center, double-blinded, placebocontrolled study in which 302 subjects were given ER injectable naltrexone (380 mg) at weeks 1 and 5. Subjects were then randomly assigned to one of three conditions for 8 weeks: buprenorphine (4 mg) + naloxone (1 mg) daily; buprenorphine (16 mg) + naloxone (4 mg) daily; or placebo. Three weekly clinic visits included observed dosing, provision of take-home medications, urine drug screens (UDS), and other assessments. The study included 11 sites across the nation (California, Oregon, Washington, Colorado, Texas, Georgia, Ohio, New York, and Washington DC) between September 2011 and March 2013. A total of 87% of potential subjects were excluded after using rigorous screening criteria for appropriateness. Follow-up assessments were conducted at 1 and 3 months post treatment. The primary outcome was UDS-corrected self-reported cocaine use during the last 4 weeks of treatment. The secondary outcomes were UDS cocaine results, medication adherence, subject attrition, and adverse events. Results: Ten participants dropped out during the study leaving a total of 292 subjects. The results of the primary outcome showed no difference in cocaine use between any of the three groups. Longitudinal analysis of UDS data during the evaluation period using generalized linear mixed equations found a statistically significant difference between BUP 16 mg and placebo [P = 0.022, odds ratio (OR) = 1.71] but not for BUP 4 mg (P = 0.105, OR = 1.05). No secondary outcome differences across groups were found for adherence, retention, or adverse events. Concordance between cocaine use (measured by negative self-report and positive UDS) showed approximately 32%; when missing UDS data were counted as positive results, the rate increased to 42%. There was no significant difference in proportions of participants achieving complete cocaine abstinence between placebo and either BUP group. A post hoc analysis of a subgroup of Bhigh use^cocaine users showed a significantly greater reduction in self-reported days of cocaine use from baseline to week 8, but this was not a planned objective of the initial study. Selfreported opioid use was reduced significantly for all groups from baseline through all times points measured, but there was no difference between groups based on UDS findings. BUP 16 mg had a larger percentage of reported opioid use at 1-month follow-up than placebo. The primary outcome failed to detect significant differences in cocaine use between treatment groups. Secondary analysis (negative UDS results) did reveal more cocaine-negative samples among the BUP 16 mg group compare to the placebo group only. There was no difference between groups in terms of adherence to treatment, retention, or adverse events. Conclusion: Buprenorphine + naloxone, used in combination with naltrexone, may be associated with very small reductions in cocaine use among people who meet DSM-IV criteria for cocaine dependence and past or current opioid abuse, but these differences were not statistically or clinically significant. Critique: The study was well designed and included 11 different sites from across the USA. The retention of participants through the 3-month follow-up visits was impressive but could have been longer. A potential flaw is that testing to verify buprenorphine use was present in only~80% of subjects at week 5 and 70% at week 8, which introduced concern about diversion. The missing UDS collections (~16% per each group) were interpreted as positive results which may have effected concordance with self-reported use. Implications for Toxicologists: This study failed to show clinically significant long-term benefits of pharmacotherapy for cocaine abuse. Toxicologists should recognize the limitations associated with both treating these patients as well as reviewing literature on this topic.
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